Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
Vanda Pharmaceuticals
Summary
The aim of this study is to investigate the safety and tolerability of trichostatin A in individuals with relapsed or refractory hematologic malignancies.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Subject is ≥ 18 years at the time of signing informed consent; * Confirmed malignant hematologic disease or lymphoid malignancy that has relapsed or is refractory to standard therapy and has exhausted all available therapies; * Presence of measurable or evaluable disease; * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2; * Contraceptives or other approved avoidance of pregnancy measures Exclusion Criteria: * Allogeneic stem cell transplant recipient presenting with graft versus host disease (GVHD) either active or requiring immunosuppression; * Con…
Interventions
- DrugTrichostatin A
Intravenous Infusion
Locations (11)
- Vanda Investigational SiteWashington D.C., District of Columbia
- Vanda Investigational SiteLafayette, Indiana
- Vanda Investigational SiteHackensack, New Jersey
- Vanda Investigational SiteSeattle, Washington
- Vanda Investigational SiteBiała Podlaska
- Vanda Investigational SiteKatowice